TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis: A Multiple Centers, Randomized, Assessor- and Participant-blind, Controlled, Cross-over Clinical Trial
Brief Summary: Uremic pruritus is a clinically significant symptom which imposes heavy impact on the quality of life of patients with chronic kidney disease undergoing hemodialysis. In order to investigate the clinical efficacy and mechanism, the investigators designed a multiple centers, randomized, assessor- and participant-blind, controlled, cross-over clinical trial. This trial will be conducted at Taichung branch, Feng-yuan branch and the Eastern branch of CMUH.


Options:
A: Arm Label: PA101B; Type: EXPERIMENTAL; Interventions: Drug: PA101B | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PA101B; Assigned to Arm(s): PA101B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Wheat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Wheat | Arm Label: Fumaria; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaria | Intervention Type: DRUG; Name: Wheat; Assigned to Arm(s): Wheat | Intervention Type: DRUG; Name: Fumaria; Assigned to Arm(s): Fumaria
C: Arm Label: laser acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser acupuncture (Olympic), Device: Sham Laser acupuncture (Olympic) | Arm Label: sham laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Laser acupuncture (Olympic), Device: Sham Laser acupuncture (Olympic) | Intervention Type: DEVICE; Name: Laser acupuncture (Olympic); Assigned to Arm(s): laser acupuncture, sham laser acupuncture | Intervention Type: DEVICE; Name: Sham Laser acupuncture (Olympic); Assigned to Arm(s): laser acupuncture, sham laser acupuncture
D: Arm Label: TRK-820 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: nalfurafine hydrochloride (TRK-820) | Arm Label: TRK-820 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: nalfurafine hydrochloride (TRK-820) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: nalfurafine hydrochloride (TRK-820); Assigned to Arm(s): TRK-820 2.5μg, TRK-820 5μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Timing of Morning Rounds for Postpartum Hospitalized Women: A Randomized Controlled Quality Improvement Trial
Brief Summary: In postpartum hospitalized women, does delayed morning rounding improve patient satisfaction?


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
B: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed rounding; Type: EXPERIMENTAL; Interventions: Behavioral: Delayed rounds | Intervention Type: BEHAVIORAL; Name: Delayed rounds; Assigned to Arm(s): Delayed rounding
C: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A
D: Arm Label: Breastfeeding Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breastfeeding Clinic | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding Clinic; Assigned to Arm(s): Breastfeeding Clinic

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fascia Iliaca Block in the Emergency Department for Analgesia After Femoral Neck Fracture
Brief Summary: Femoral neck fracture is very common in the elderly and can produce severe to moderate pain. As this pathology is not life-threatening, waiting time in the emergency department may be prolonged due to the high number of unforeseen cases with patients remaining in pain.

Fascia iliaca block consists of injecting local anaesthetics below the fascia iliaca, resulting in the anaesthesia of the femoral, the lateral cutaneous and the obturator nerves, with effective analgesia.


Options:
A: Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham injection | Intervention Type: PROCEDURE; Name: Fascia iliaca block; Assigned to Arm(s): Fascia iliaca block | Intervention Type: PROCEDURE; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: femoral group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: femoral nerve catheter, Drug: femoral group | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: femoral nerve catheter, Drug: control group | Intervention Type: PROCEDURE; Name: femoral nerve catheter; Assigned to Arm(s): control group, femoral group | Intervention Type: DRUG; Name: femoral group; Assigned to Arm(s): femoral group | Intervention Type: DRUG; Name: control group; Assigned to Arm(s): control group
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block arm | Intervention Type: PROCEDURE; Name: Fascia iliaca block arm; Assigned to Arm(s): Fascia iliaca block
D: Arm Label: Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ropivacaine | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Ropivacaine, Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Feeding Infant Formula With Enriched Protein Fractions
Brief Summary: This study is intended to measure declarative or stored memory and behavior between infants who consume one of two infant formulas through approximately one year of age.


Options:
A: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
B: Arm Label: IF-VLP (very low protein); Type: EXPERIMENTAL; Interventions: Other: Infant formula | Arm Label: IF-LP (low protein); Type: OTHER; Interventions: Other: Infant formula | Arm Label: IF-CSP (control standard protein); Type: OTHER; Interventions: Other: Infant formula | Arm Label: HM (human milk); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): IF-CSP (control standard protein), IF-LP (low protein), IF-VLP (very low protein)
C: Arm Label: Cow's milk-based infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Cow's milk-based infant formula | Arm Label: Cow milk-based infant formula with enriched protein fractions; Type: EXPERIMENTAL; Interventions: Other: Cow milk-based infant formula with enriched protein fractions | Intervention Type: OTHER; Name: Cow's milk-based infant formula; Assigned to Arm(s): Cow's milk-based infant formula | Intervention Type: OTHER; Name: Cow milk-based infant formula with enriched protein fractions; Assigned to Arm(s): Cow milk-based infant formula with enriched protein fractions
D: Arm Label: Study Formula (SF); Type: EXPERIMENTAL; Interventions: Other: Study Formula (SF), Other: Comparator Formula (CF) | Arm Label: Comparator Formula (CF); Type: ACTIVE_COMPARATOR; Interventions: Other: Study Formula (SF), Other: Comparator Formula (CF) | Arm Label: Human Milk Reference Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Study Formula (SF); Assigned to Arm(s): Comparator Formula (CF), Study Formula (SF) | Intervention Type: OTHER; Name: Comparator Formula (CF); Assigned to Arm(s): Comparator Formula (CF), Study Formula (SF)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis
Brief Summary: The purpose of this study is to prove the superiority of a 6-weeks treatment with budesonide effervescent tablets versus placebo for the induction of clinico-pathological remission in patients with acute eosinophilic esophagitis.


Options:
A: Arm Label: Oral Viscous Budesonide (OVB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Viscous Budesonide, Drug: Placebo inhaler | Arm Label: Active Fluticasone MDI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone MDI, Drug: Placebo slurry | Intervention Type: DRUG; Name: Oral Viscous Budesonide; Assigned to Arm(s): Oral Viscous Budesonide (OVB) | Intervention Type: DRUG; Name: Fluticasone MDI; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo slurry; Assigned to Arm(s): Active Fluticasone MDI | Intervention Type: DRUG; Name: Placebo inhaler; Assigned to Arm(s): Oral Viscous Budesonide (OVB)
B: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide 1mg orodispersible tablet twice daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo orodispersible tablet twice daily | Intervention Type: DRUG; Name: Budesonide 1mg orodispersible tablet twice daily; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: Placebo orodispersible tablet twice daily; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: QAX576 placebo | Arm Label: QAX576; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAX576 | Intervention Type: DRUG; Name: QAX576 placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: QAX576; Assigned to Arm(s): QAX576
D: Arm Label: Mepolizumab 0.55 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Arm Label: Mepolizumab 2.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Arm Label: Mepolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: mepolizumab | Intervention Type: DRUG; Name: mepolizumab; Assigned to Arm(s): Mepolizumab 0.55 mg/kg, Mepolizumab 10 mg/kg, Mepolizumab 2.5 mg/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled and Prospective Randomised Study to Compare Complete Lymph Node Dissection Versus Watchful Waiting in Patients With Malignant Melanoma With a Tumour Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node
Brief Summary: Sentinel lymph node biopsy (SLNB) is considered as standard diagnostic procedure in melanoma patients carrying a reasonable risk for metastases. In numerous studies the prognostic role of micro metastases in the sentinel node (SN) was described. However, the prognostic value of a complete lymph node dissection in patients with a positive SN is still unclear.

This study was planned to analyse the survival outcome of patients with a positive SN receiving complete lymphadenectomy versus watchful waiting.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
B: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
C: Arm Label: Completion Lymphadenectomy; Type: EXPERIMENTAL; Interventions: Procedure: Completion Lymphadenectomy | Arm Label: Clinical Monitoring (Palpation and node ultrasound); Type: EXPERIMENTAL; Interventions: Procedure: Clinical Monitoring (Palpation and node ultrasound) | Intervention Type: PROCEDURE; Name: Completion Lymphadenectomy; Assigned to Arm(s): Completion Lymphadenectomy | Intervention Type: PROCEDURE; Name: Clinical Monitoring (Palpation and node ultrasound); Assigned to Arm(s): Clinical Monitoring (Palpation and node ultrasound)
D: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Creative Music Therapy for Premature Infants: Testing a Possible Influence on Brain Structure, Function and Neurobehavioral Outcome
Brief Summary: This study investigates whether creative music therapy applied to premature infants will facilitate brain growth and development at term equivalent assessed by magnetic resonance imaging. Secondary objective are improvement of neurobehavioral outcomes of premature infants at 24 months, as well as at 5 years of age.


Options:
A: Arm Label: MT during and after NICU; Type: EXPERIMENTAL; Interventions: Behavioral: MT during NICU, Behavioral: MT after NICU, Other: Standard care | Arm Label: MT during NICU; Type: EXPERIMENTAL; Interventions: Behavioral: MT during NICU, Other: Standard care | Arm Label: MT after NICU; Type: EXPERIMENTAL; Interventions: Behavioral: MT after NICU, Other: Standard care | Arm Label: No MT; Type: EXPERIMENTAL; Interventions: Other: Standard care | Intervention Type: BEHAVIORAL; Name: MT during NICU; Assigned to Arm(s): MT during NICU, MT during and after NICU | Intervention Type: BEHAVIORAL; Name: MT after NICU; Assigned to Arm(s): MT after NICU, MT during and after NICU | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): MT after NICU, MT during NICU, MT during and after NICU, No MT
B: Arm Label: Multisensory Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Therapist skin-to-skin Care, Device: Contingent parent's voice exposure, Behavioral: Parental skin-to-skin care, Device: Recorded parent's voice | Arm Label: Standard of Care; Type: OTHER; Interventions: Behavioral: Parental skin-to-skin care, Device: Recorded parent's voice | Intervention Type: BEHAVIORAL; Name: Therapist skin-to-skin Care; Assigned to Arm(s): Multisensory Intervention | Intervention Type: DEVICE; Name: Contingent parent's voice exposure; Assigned to Arm(s): Multisensory Intervention | Intervention Type: BEHAVIORAL; Name: Parental skin-to-skin care; Assigned to Arm(s): Multisensory Intervention, Standard of Care | Intervention Type: DEVICE; Name: Recorded parent's voice; Assigned to Arm(s): Multisensory Intervention, Standard of Care
C: Arm Label: music therapy; Type: EXPERIMENTAL; Interventions: Procedure: Music Therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Music Therapy; Assigned to Arm(s): music therapy
D: Arm Label: Early Vocal Contact; Type: EXPERIMENTAL; Interventions: Behavioral: Early Vocal Contact | Arm Label: Behavioral observation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Observation | Intervention Type: BEHAVIORAL; Name: Early Vocal Contact; Assigned to Arm(s): Early Vocal Contact | Intervention Type: BEHAVIORAL; Name: Behavioral Observation; Assigned to Arm(s): Behavioral observation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D
Brief Summary: The optimal vitamin D replacement dose during pregnancy remains undefined. Therefore, the aim of this study is to test the hypothesis that a daily equivalent dose of vitamin D of 3,000 IU/day is needed for Middle Eastern women, to optimize maternal vitamin D level and neonatal musculoskeletal parameters, specifically knee-heel length at birth and bone mineral content at one month of age.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: Low dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Euro D | Arm Label: High dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Euro D | Intervention Type: DIETARY_SUPPLEMENT; Name: Euro D; Assigned to Arm(s): Low dose vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Euro D; Assigned to Arm(s): High dose vitamin D
C: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
D: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial to Evaluate the Effectiveness of Vibration and External Cold (Buzzy Device) for Pain Relief During Venipuncture or Intravenous Cannulation in Children With Intellectual Disability.
Brief Summary: Needle procedures are the most common and important source of pain and distress in children in the health care setting. Children with intellectual disability from any cause experience pain more frequently than healthy children. They often require venipuncture or IV cannulation for diagnostic or therapeutic procedures. Pain in this population is often unrecognised because these patients are frequently unable to self-report their pain. Now it's possible to measure pain in children with intellectual disability with specific pain scales, like NCCPC-PV (Non-Communicating Children's Pain Checklist, Post-operative Version).

The efficacy of a device combining vibration and cold for pain relief during venipuncture or IV cannulation has been recently reported in children. The device's actions are based on the Gate Control Theory, whereby cold and vibrations stimulate large fiber and inhibitory neurons to interrupt nociception. This non-pharmacologic technique for pain relief could be useful in this kind of patients in emergency department. To date, there is no study that validated Buzzy device for pain relief in children with intellectual disability.

The aim of this study is to test the effectiveness of Buzzy® (a device that provides cold and vibration), in reducing the pain during venipuncture or IV cannulation, in children with intellectual disability.


Options:
A: Arm Label: Standard technique; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard technique | Arm Label: Parent participation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Parent participation technique | Intervention Type: BEHAVIORAL; Name: Standard technique; Assigned to Arm(s): Standard technique | Intervention Type: BEHAVIORAL; Name: Parent participation technique; Assigned to Arm(s): Parent participation technique
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: info group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: info | Arm Label: smartphone group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smartphone | Arm Label: smartphone and info group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: info, Behavioral: smartphone | Intervention Type: BEHAVIORAL; Name: info; Assigned to Arm(s): info group, smartphone and info group | Intervention Type: BEHAVIORAL; Name: smartphone; Assigned to Arm(s): smartphone and info group, smartphone group
C: Arm Label: humanoid robot distration; Type: N/A; Interventions: N/A | Arm Label: control; Type: N/A; Interventions: N/A
D: Arm Label: Buzzy® device; Type: EXPERIMENTAL; Interventions: Device: Buzzy® device | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Buzzy® device; Assigned to Arm(s): Buzzy® device

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alive & Thrive Evaluation in Burkina Faso
Brief Summary: The time between birth and age 24 months provides a unique opportunity to impact the long-term health and development of children through improved infant and young child feeding practices. In Burkina Faso, the prevalence of exclusive breastfeeding is currently around 25% in infants younger than six months.

The purpose of this study is to evaluate whether the Alive \& Thrive intervention package, consisting of interpersonal counselling and community mobilisation activities, can increase the exclusive breastfeeding rate among infants younger than six months to at least 50% using a cluster randomised design.


Options:
A: Arm Label: Obesity Prevention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity Prevention Group | Arm Label: Injury Prevention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Injury Prevention Group | Intervention Type: BEHAVIORAL; Name: Obesity Prevention Group; Assigned to Arm(s): Obesity Prevention Group | Intervention Type: BEHAVIORAL; Name: Injury Prevention Group; Assigned to Arm(s): Injury Prevention Group
B: Arm Label: A&T Intervention Communes; Type: EXPERIMENTAL; Interventions: Behavioral: A&T infant and young child feeding intervention | Arm Label: Control Communes; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A&T infant and young child feeding intervention; Assigned to Arm(s): A&T Intervention Communes
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity; Type: OTHER; Interventions: Other: Telephone-based breastfeeding peer counseling | Arm Label: High Intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone-based breastfeeding peer counseling | Intervention Type: OTHER; Name: Telephone-based breastfeeding peer counseling; Assigned to Arm(s): High Intensity, Low Intensity
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation | Intervention Type: BEHAVIORAL; Name: Relaxation; Assigned to Arm(s): Relaxation

Answer: B